Montelukast in Children With Wheezing

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study children with recurrent wheezing (>/= 2 episodes in the last 6 months)and aged less than 2 years will be enrolled as outpatients. They will undergo lung function evaluation by Rint and by assessment of the flow curves at baseline and after 4 weeks of treatment with Montelukast 4 mg/day. Symptom dairies will be filled by parents during the study period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universita di Verona
• Collaborator: Azienda Ospedaliera Universitaria Policlinico
• Treatments: Leukotriene Antagonists; Montelukast

Criteria

Inclusion Criteria:

• Age between 6-24 months

• Patients with recurrent wheezing (at least 2 episodes in the last 6 months)

• Patients with symptoms at enrollment

Exclusion Criteria:

• Chronic respiratory diseases (cystic fibrosis, chronic lung disease) symptoms at visit 1 that require hospital admission